News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Abbott Laboratories’ Kaletra HIV-Drug Patent Rejected in India, Allowing Cipla Ltd. Copies
January 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Abbott Laboratories was refused copyright protection on its AIDS drug Kaletra by India’s patent office, allowing Cipla Ltd. and other generic-drug companies to continue selling copies.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Abbott Laboratories
MORE ON THIS TOPIC
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
December 22, 2025
·
1 min read
·
Annalee Armstrong
China
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour
December 17, 2025
·
1 min read
·
Tristan Manalac
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
December 17, 2025
·
2 min read
·
Heather McKenzie
Insights
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback
December 17, 2025
·
3 min read
·
Jennifer Smith-Parker
